Using the AACR Health Disparities Report to Drive Change in Cancer Care

Commentary
Video

The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.

The American Association for Cancer Research (AACR) Health Disparities Report is a powerful tool that can help educate those in the oncology community on health equity issues among patients with cancer, according to Robert A. Winn, MD.

Winn described his experiences with organizing the AACR Health Disparities Reports since the publication of the first in 2020. He stated that he was “happy” to be involved in this effort to help spread awareness of cancer disparities.

Winn, director and Lipman Chair in Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, senior associate for Cancer Innovation, and professor of Pulmonary Disease and Critical Cancer Medicine at VCU School of Medicine, also touched on how working with other professional bodies such as the American Cancer of Clinical Oncology (ASCO) may achieve the goal of educating others on heath disparity issues in oncology.

Transcript:

The education part of this is exciting for us. I hope that the AACR Health Disparities Report is just 1 tool to not only get my colleagues but to get people within the community and get those people who are in charge of our resources a little bit more up-to-speed and aware. This report has, on its own, been substantiated. I was part of the first one in 2020, and part of the second one in 2022. I’m happy to be part of [the 2023] one as well and leading the charge of the 2024 report. That’s one element that we hope will be able to help educate people and bring awareness. The other one is just [the] good old-fashioned [strategy of] having our professional bodies, whether they’re AACR, AACI [Association of American Cancer Institutes], American Cancer Society, or ASCO [American Society of Clinical Oncology] all working on one accord, and that is to bring to the attention that cancer is not like it used to be in the 1950s. It is not necessarily a death sentence if you can get to the right place and get the right care at the right time.

Reference

Experts forecast 2024, part 2: achieving cancer health equity. News release. AACR. January 12, 2024. Accessed February 16, 2024. https://shorturl.at/cMQR8

Recent Videos
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Related Content